Vorapaxar: Targeting a novel antiplatelet pathway

P and T

Volumn 36, Issue 9, 2011, Pages 564-568

  Abdulsattar, Younos ^a,b   Ternas, Theologia ^b   Garcia, Danielle ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORAPAXAR;

CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; SIGNAL TRANSDUCTION;

EID: 80052569494     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (19)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST segment elevation myocardial infarction. J Am Coll Cardiol 2007; 50:1-157
2. The TRA·CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA·CER) trial: Study design and rationale. Am Heart J 2009;158:327-334
3. Plavix, package insert. Bridgewater, N.J.: Bristol Meyers Squibb/Sanofi Pharmaceuticals Partnership; February 2011
4. Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010;17:156-164.
5. Macaulay TE, Allen C, Ziad KM. Thrombin receptor antagonism: The potential of antiplatelet medication SCH 530348. Exp Opin Pharmacother 2010;11:1015-1022
6. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008;51: 3061-3064
7. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic, and clinical profile of novel antiplatelet drugs targeting vascular disease. Br J Pharmacol 2010;159:502-517
8. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial. Am Heart J 2009;158;335-341
9. National Center for Biotechnology Information, National Institutes of Health. Vorapaxar. Available at: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10077130. Accessed August 2, 2011
10. Kosoglou T, Reyderman L, Fales RR, et al. Pharmacodynamics and pharmacokinetics of a novel protease-activated receptor (PAR-1) antagonist SCH 530348 (Abstract) Circulation 2005;112(Suppl II): II-32
11. Kosoglou T, Reyderman L, Tiessen R, et al. TRAP-induced platelet aggregation following single and multiple rising doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers (Abstract).Clin Pharmacol Ther 2009; 85(Suppl 1):S21
12. Kosoglou T, Reyderman L, Kassera C, et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects (Abstract). Clin Pharmacol Ther 2008;83(Suppl 1): S55
13. Reyderman L, Kosoglou T, Tseng J, et al. The effect of food and antacid on pharmacokinetics of SCH 530348 in healthy subjects (Abstract). Clin Pharmacol Ther 2009;85(Suppl 1):S21
14. Reyderman L, Kosoglou T, Kasserra C, et al. Lack of ethnic differences in the pharmacodynamics and pharmacokinetics of SCH 530348, a novel oral antiplatelet agent, in Japanese and Caucasian subjects (Abstract). Clin Pharmacol Ther 2009;85(Suppl 1):S21.
15. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebocontrolled phase II study. Lancet 2009; 373:919-928.
16. Shinohara Y, Goto S, Doi M, et al. Safety of the novel protease-activated receptor1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc, October 13, 2010 (online). Accessed March 1, 2011.
17. Merck Statement on Changes to Clinical Studies of Vorapaxar. January 13, 2011. Available at: www.merck.com/newsroom/news-release-archive/research-anddevelopment/2011_0113.html. Accessed March 1, 2011
18. Chintala M, Vemulapalli S, Kurowski S, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys (Abstract). Arterioscler Thromb Vasc Biol 2008;28:e138-e139
19. Chintala M, Shimizu K, Ogawa M, et al. Basic and translational research on proteinase-activated receptors: Antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci 2008;108:433-438.